RxDoctor Payments Data

Toan Vu, MD

Neurology · San Marcos, TXNPI 1760463293

Payments from drug & device makers

$39,048in general payments, 2019–2025

Across 2,436 payments — averaging $16.03 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Teva Pharmaceuticals USA, Inc.$5K
  • UCB, Inc.$3K
  • Acadia Pharmaceuticals Inc$3K
  • Neurocrine Biosciences, Inc.$2K
  • AbbVie$2K
  • Neurelis, Inc.$2K
  • plus $22K from 54 others

What the payments were for

  • Speaking & faculty fees$2791%
  • Food & beverage$38,62499%
  • Education$1450%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Teva Pharmaceuticals USA, Inc.400$4,767
UCB, Inc.155$3,341
Acadia Pharmaceuticals Inc215$2,569
Neurocrine Biosciences, Inc.140$2,203
AbbVie(2 entities)162$2,091
Neurelis, Inc.59$1,563
Amneal Pharmaceuticals LLC89$1,306
MDD US Operations, LLC56$1,265
Pfizer84$1,231
Lilly USA, LLC92$1,204
Lundbeck LLC61$1,129
Eisai Inc.52$1,041
Acorda Therapeutics, Inc53$1,028
Abbott34$876
Medtronic(2 entities)37$859
Catalyst Pharmaceuticals, Inc.45$824
EMD Serono, Inc.83$804
Kyowa Kirin, Inc.38$615
GE HealthCare35$558
Novartis37$531
Amgen27$516
Upsher-smith Laboratories LLC32$496
Adamas Pharmaceuticals, Inc.42$481
Supernus Pharmaceuticals, Inc.52$474
Argenx US, Inc.23$456
Nevro Corp.5$455
CSL Behring22$450
SK Life Science, Inc.27$391
Grifols USA, LLC17$362
Octapharma USA, Inc.15$343
AstraZeneca17$337
Biogen18$324
Johnson & Johnson10$316
Otsuka America Pharmaceutical, Inc.19$283
Biohaven Pharmaceutical Holding Company Ltd.16$245
Genentech USA, Inc.12$225
Tanabe Pharma America, Inc.10$215
Merz Pharmaceuticals, LLC6$210
Axsome Therapeutics, Inc.12$195
Amylyx Pharmaceuticals, Inc.11$192
Scilex Pharmaceuticals Inc.11$183
Corium, LLC7$177
Takeda Pharmaceuticals U.S.A., Inc.8$169
Alnylam Pharmaceuticals Inc.7$152
Vertical Pharmaceuticals, LLC9$124
Avion Pharmaceuticals6$118
Averitas Pharma Inc.6$115
Merz North America, Inc.6$102
Globus Medical1$101
Biohaven Pharmaceuticals, Inc.5$97
Azurity Pharmaceuticals, Inc.5$96
Jazz Pharmaceuticals Inc.5$96
GRT US Holding, Inc.6$89
Arbor Pharmaceuticals, Inc.5$76
Sunovion Pharmaceuticals Inc.2$54
Shire North American Group Inc3$52
Bausch Health US, LLC2$44
Mallinckrodt Hospital Products Inc.2$41
Aquestive Therapeutics, Inc.2$33
Life Molecular Imaging Ltd2$31

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$39,048 in reported general payments places this provider in the 80th percentile of 1,246 neurology providers in Texas.

See all neurology providers in Texas

Medicare billing

Part B allowed, 2024
$130,481
Medicare patients
432
Services billed
1,152

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Nurtec OdtRimegepant Sulfate41$58,138
RexultiBrexpiprazole22$34,832
Aimovig AutoinjectorErenumab-Aooe28$26,674
Emgality PenGalcanezumab-Gnlm35$25,773
NayzilamMidazolam13$25,677
Ajovy SyringeFremanezumab-Vfrm22$19,800
NeuproRotigotine11$17,738
BriviactBrivaracetam11$15,076
UbrelvyUbrogepant11$11,947
Levetiracetam137$5,101
Lacosamide41$3,601
Oxcarbazepine48$3,105
Gabapentin146$2,932
Nortriptyline Hcl167$2,477
Modafinil24$2,025

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
UCB, Inc.Nayzilam, Neupro, Briviact$3,341$58,49135 claims
PfizerNurtec Odt$1,231$58,13841 claims
Otsuka America Pharmaceutical, Inc.Rexulti$283$34,83222 claims
AbbVieUbrelvy$2,091$11,94711 claims
Amneal Pharmaceuticals LLCPyridostigmine Bromide$1,306$1,61621 claims
Upsher-smith Laboratories LLCTopiramate$496$1,455126 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 1,246 neurology providers in Texas.

Other neurology in San Marcos

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →